a comparison of bispecific antibodies emerging in multiple myeloma
Published 2 years ago • 251 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
10:11
monumental-1: talquetamab in r/r multiple myeloma
-
5:06
bispecific antibodies: late side effects
-
1:53
infections following anti-bcma bispecific antibodies for multiple myeloma
-
1:22
risk of infection in patients with multiple myeloma treated with bispecific antibodies
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
1:38
the efficacy of cevostamab in r/r multiple myeloma and the importance of bispecific antibodies
-
1:19
infectious toxicities in patients with multiple myeloma treated with bispecific antibodies
-
0:41
fcrh5 & gprc5d bispecific antibodies: antigen targets beyond bcma for multiple myeloma
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:56
the exciting future of bispecific antibodies
-
2:44
dual-targeting bispecific antibody alnuctamab in r/r multiple myeloma
-
2:55
bispecific antibodies for myeloma: highlights from ash 2020
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape